Q2 2019 Evelo Biosciences Inc Earnings Call Transcript
Good morning, and welcome to Evelo's Conference Call for Initial Data Results for Clinical Trials EDP1815 and EDP1066. (Operator Instructions)
At this time, I'd like to turn the call over to Stefan Riley of Evelo. Please proceed.
Thank you, operator. This morning, we issued a press release that outlines the topics that we plan to discuss today. This release is available at www.evelobio.com under the Investors tab.
Today in our call, Simba Gill, Evelo's CEO, together with Duncan McHale, our Chief Medical Officer, will review the positive data from EDP1815 and EDP1066 and their significance on the company's strategy and future clinical plans.
Before we begin, I would like to remind everyone that statements made during this conference call that do not relate to matters of historical fact, including statements about our objectives and anticipated clinical milestones for 2019 and 2020, the potential of any of our monoclonal microbials and clinical data, the timing and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |